Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
2.440
+0.020 (0.83%)
At close: Oct 9, 2026, 4:00 PM EDT
2.480
+0.040 (1.64%)
After-hours: Oct 9, 2026, 7:36 PM EDT
Atossa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
24.35M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immutep | 13.79M |
| Evaxion | 7.49M |
| Kyntra Bio | 4.62M |
| Seres Therapeutics | 1.88M |
| BeyondSpring | 1.88M |
| ABVC BioPharma | 797.92K |
| aTyr Pharma | 190.00K |
ATOS News
- 1 day ago - Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value - PRNewsWire
- 11 days ago - Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher - PRNewsWire
- 16 days ago - Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging - PRNewsWire
- 22 days ago - Atossa Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PRNewsWire
- 2 months ago - Atossa Therapeutics Quarterly report: Q2 2026 - Filings
- 2 months ago - Atossa Therapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer - PRNewsWire